Skip to main content

Advertisement

SpringerLink
Log in

Primary Central Nervous System Lymphoma

  • Neuro-oncology (Neoplasms)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Management goals for patients with primary central nervous system lymphoma (PCNSL) include long-term disease control, management of neurologic complications, and preservation of neurocognitive function. Various treatment options can achieve several of these goals. Chemotherapy as monotherapy or as combination therapy has emerged as the cornerstone of therapy for patients with newly diagnosed PCNSL. Outside of a clinical trial, patients with newly diagnosed PCNSL should receive high-dose intravenous methotrexate (MTX) as a single agent or as part of a combination regimen with radiation therapy reserved for relapse. The regimen should have an adequate MTX dose (>3 g/m2) to reach cytotoxic concentrations in the cerebrospinal fluid (CSF) to treat occult leptomeningeal disease (LMD). Alternative modes of chemotherapy delivery for selected patients, preferably in the context of a clinical trial, include high-dose chemotherapy with autologous stem cell rescue and intra-arterial chemotherapy with blood–brain barrier disruption. Whole brain radiation therapy (WBRT) in standard doses and fractionation carries an unacceptable rate of long-term neurocognitive toxicity. However, lower doses in daily divided fractions may offer the possibility of adding this modality with preservation of cognition but should be performed only in the context of a clinical trial. The long-term efficacy and toxicity of this approach is currently under investigation. Certain presentations of PCNSL require different strategies. Patients with ocular lymphoma at diagnosis should receive high-dose MTX as this drug can reach cytotoxic intravitreal concentrations. Recurrence in the eyes is managed with intravitreal chemotherapy including MTX or rituximab or with radiation therapy. The field of treatment (eyes vs whole brain) should be individualized. Intrathecal (IT) MTX should be included in the treatment regimen for those patients with a positive CSF cytology, or in regimens in which lower doses of MTX are delivered over longer periods of time. It is probably reasonable to withhold IT chemotherapy in those patients who have no detectable subarachnoid disease and who can receive higher doses of MTX (>3 g/m2) over shorter infusion periods (2–4 h). Patients who develop leptomeningeal involvement despite high- dose MTX can be managed with IT chemotherapy such as liposomal cytarabine or MTX or even rituximab. Areas of bulky or symptomatic LMD should probably be treated with radiation therapy as well. Because PCNSL is an uncommon disease, entry into clinical trials must be pursued to advance the state of the art.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H: Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006, 106:128–135.

    Article  CAS  PubMed  Google Scholar 

  2. Ferreri AJ, Blay JY, Reni M, et al.: Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003, 21:266–272.

    Article  PubMed  Google Scholar 

  3. Abrey LE, Ben-Porat L, Panageas KS, et al.: Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006, 24:5711–5715.

    Article  PubMed  Google Scholar 

  4. Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23:9–17.

    CAS  PubMed  Google Scholar 

  5. Shibamoto Y, Ogino H, Hasegawa M, et al.: Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 2005, 62:809–813.

    PubMed  Google Scholar 

  6. Abrey LE, DeAngelis LM, Yahalom J: Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859–863.

    CAS  PubMed  Google Scholar 

  7. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000, 18:3144–3150.

    CAS  PubMed  Google Scholar 

  8. Balmaceda C, Gaynor JJ, Sun M, et al.: Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 1995, 38:202–209.

    Article  CAS  PubMed  Google Scholar 

  9. Quijano S, López A, Manuel Sancho J, et al.: Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009, 27:1462–1469.

    Article  CAS  PubMed  Google Scholar 

  10. Ferreri AJ, Reni M, Pasini F, et al.: A multicenter study of treatment of primary CNS lymphoma. Neurology 2002, 58:1513–1520.

    CAS  PubMed  Google Scholar 

  11. Ekenel M, Iwamoto FM, Ben-Porat LS, et al.: Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008, 113:1025–1031.

    Article  CAS  PubMed  Google Scholar 

  12. Bessell EM, Lopez-Guillermo A, Villa S, et al.: Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002, 20:231–236.

    Article  CAS  PubMed  Google Scholar 

  13. Shah GD, Yahalom J, Correa DD, et al.: Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007, 25:4730–4735.

    Article  CAS  PubMed  Google Scholar 

  14. DeAngelis LM, Yahalom J, Thaler HT, et al.: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992, 10:635–643.

    CAS  PubMed  Google Scholar 

  15. Schultz C, Scott C, DeAngelis L, et al: Radiation therapy (RT) alone vs. pre-RT chemotherapy (CTX) for the treatment of primary CNS lymphoma (PCNSL): Age matched survival analysis of RTOG 83-15 and 93-10. J Clin Oncol 2000, 19:159a.

    Google Scholar 

  16. Gerstner ER, Carson KA, Grossman SA, Batchelor TT: Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 2008, 70:401–402.

    Article  PubMed  Google Scholar 

  17. Zhu JJ, Gerstner ER, Engler DA, et al.: High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009, 11(2):211–215.

    Article  CAS  PubMed  Google Scholar 

  18. Ferreri AJ, Reni M, Foppoli M, et al.: High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009, 374:1512–1520.

    Article  CAS  PubMed  Google Scholar 

  19. Neuwelt EA, Frenkel EP, Rapoport S, Barnett P: Effect of osmotic blood–brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 1980, 7:36–43.

    Article  CAS  PubMed  Google Scholar 

  20. Angelov L, Doolittle ND, Kraemer DF, et al.: Blood–brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009, 27:3503–3509.

    Article  CAS  PubMed  Google Scholar 

  21. Abrey LE, Moskowitz CH, Mason WP, et al.: Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003, 21:4151–4156.

    Article  CAS  PubMed  Google Scholar 

  22. Illerhaus G, Müller F, Feuerhake F, et al.: High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008, 93:147–148.

    Article  CAS  PubMed  Google Scholar 

  23. Jahnke K, Thiel E, Martus P, et al.: Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 2006, 80:159–165.

    Article  PubMed  Google Scholar 

  24. Plotkin SR, Betensky RA, Hochberg FH, et al.: Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004, 10:5643–5646.

    Article  CAS  PubMed  Google Scholar 

  25. Nguyen PL, Chakravarti A, Finkelstein DM, et al.: Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005, 23:1507–1513.

    Article  PubMed  Google Scholar 

  26. Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE: Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 2007, 69:1178–1182.

    Article  PubMed  Google Scholar 

  27. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004, 63:901–903.

    CAS  PubMed  Google Scholar 

  28. Voloschin AD, Betensky R, Wen PY, et al.: Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008, 86:211–215.

    Article  CAS  PubMed  Google Scholar 

  29. Soussain C, Hoang-Xuan K, Taillandier L, et al.: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008, 26:2512–2518.

    Article  PubMed  Google Scholar 

  30. Jahnke K, Thiel E, Abrey LE, et al.: Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol 2007, 1:247–258.

    CAS  PubMed  Google Scholar 

  31. Batchelor TT, Kolak G, Ciordia R, et al.: High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 2003, 9:711–715.

    CAS  PubMed  Google Scholar 

  32. Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA: Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 1997, 115:1152–1156.

    CAS  PubMed  Google Scholar 

  33. Grimm SA, McCannel CA, Omuro AM, et al.: Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008, 71:1355–1360.

    Article  CAS  PubMed  Google Scholar 

  34. Kitzmann AS, Pulido JS, Mohney BG, et al.: Intraocular use of rituximab. Eye (Lond) 2007, 21:1524–1527.

    CAS  Google Scholar 

  35. Glantz MJ, Cole BF, Recht L, et al.: High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 1998, 16:1561–1567.

    CAS  PubMed  Google Scholar 

  36. Khan RB, Shi W, Thaler HT, et al.: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002, 58:175–178.

    Article  PubMed  Google Scholar 

  37. Pels H, Juergens A, Glasmacher A, et al.: Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009, 91:299–305.

    Article  CAS  PubMed  Google Scholar 

  38. Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110–3116.

    CAS  PubMed  Google Scholar 

  39. Rubenstein JL, Fridlyand J, Abrey L, et al.: Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25:1350–1356.

    Article  CAS  PubMed  Google Scholar 

  40. McAllister LD, Doolittle ND, Guastadisegni PE, et al.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46:51–60.

    Article  CAS  PubMed  Google Scholar 

  41. O’Brien P, Roos D, Pratt G, et al.: Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000, 18:519–526.

    PubMed  Google Scholar 

  42. DeAngelis LM, Seiferheld W, Schold SC, et al.: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93–10. J Clin Oncol 2002, 20:4643–4648.

    Article  PubMed  Google Scholar 

  43. Poortmans PMP, Kluin-Neiemans HC, Haaxma-Reiche H, et al.: High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21:4483–4488.

    Article  CAS  PubMed  Google Scholar 

  44. Batchelor T, Carson K, O’Neill A, et al.: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol 2003, 21:1044–1049.

    Article  CAS  PubMed  Google Scholar 

  45. Pels H, Schmidt-Wolf IG, Glasmacher A, et al.: Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003, 21:4489–4495.

    Article  CAS  PubMed  Google Scholar 

  46. Omuro AM, DeAngelis LM, Yahalom J, et al.: Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 2005, 64:69–74.

    Article  CAS  PubMed  Google Scholar 

  47. Herrlinger U, Schabet M, Brugger W, et al.: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002, 51:247–252.

    Article  CAS  PubMed  Google Scholar 

  48. Gavrilovic IT, Hormigo A, Yahalom J, et al.: Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006, 24:4570–4574.

    Article  CAS  PubMed  Google Scholar 

  49. Ferreri AJ, Dell’Oro S, Foppoli M, et al.: MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006, 66:1435–1438.

    Article  CAS  PubMed  Google Scholar 

  50. Herrlinger U, Brugger W, Bamberg M, et al.: PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000, 54:1707–1708.

    CAS  PubMed  Google Scholar 

  51. Arellano-Rodrigo E, Lopez-Guillermo A, Bessell EM, et al.: Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 2003, 70:219–224.

    Article  CAS  PubMed  Google Scholar 

  52. Tyson RM, Siegal T, Doolittle ND, et al.: Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leuk Lymphoma 2003, 44:627–633.

    Article  CAS  PubMed  Google Scholar 

  53. Fischer L, Thiel E, Klasen HA, et al.: Prospective trial of topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006, 17:1141–1145.

    Article  CAS  PubMed  Google Scholar 

  54. Reni M, Zaja F, Mason W, et al.: Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007, 96:864–867.

    Article  CAS  PubMed  Google Scholar 

  55. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al.: Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007, 110:2528–2534.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

David Peereboom has received research support and honoraria from Schering Plough.

Author information

Authors and Affiliations

  1. Brain Tumor and Neuro-Oncology Center/Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH, 44195, USA

    Manmeet S. Ahluwalia MD & David M. Peereboom MD

Authors
  1. Manmeet S. Ahluwalia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Peereboom MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David M. Peereboom MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahluwalia, M.S., Peereboom, D.M. Primary Central Nervous System Lymphoma. Curr Treat Options Neurol 12, 347–359 (2010). https://doi.org/10.1007/s11940-010-0076-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-010-0076-7

Keywords

Search

Navigation